Sigma-Aldrich entered into a worldwide licensing agreement with Australia’s Commonwealth Scientific and Industrial Research Organization (CSIRO) to manufacture and sell reversible addition-fragmentation chain transfer (RAFT) agents, organic molecules that can be added to polymerization reactions to precisely control molecular weights and structures of polymers. Under the terms of the agreement, Sigma-Aldrich has the rights to manufacture and sell the RAFT agents worldwide for all R&D applications.

Polymers designed using RAFT technology can be used to prepare materials with unique properties controlled by their nanometer-scale molecular architecture in industries such as biomedical, specialty chemical, and personal care, Sigma-Aldrich explains. The RAFT method is applicable to a wide range of monomers and experimental conditions. Sigma-Aldrich currently offers seven RAFT agents that can be supplied in quantities from standard 1 g and 5 g packs to several hundred grams and expects to make additional RAFT agents available later in 2010.

Previous articleAbbott’s $450M Acquisition Offer for Facet Trumps Biogen Idec’s
Next articleIpsen Licenses Preclinical MSH and Ghrelin Agonist Programs to Rhythm Pharmaceuticals